ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1045

Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Abstract Number: 1046

Shifting Paradigms in Drug Spending: A Study of Medicare Part D versus Emerging Pharmacy Models in Rheumatology
Abstract Number: 1047

Impact of Treatment Switching on Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
Abstract Number: 1048

Self-Perception of Oral Health and Habits in Patients with Sjögren’s Syndrome, Rheumatoid Arthritis, and Systemic Lupus Erythematosus
Abstract Number: 1049

Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology
Abstract Number: 1050

The Cost-effectiveness of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) for Patients with Knee Osteoarthritis and Obesity
Abstract Number: 1051

Healthcare Costs and Resource Utilization Associated with Long-term Medium-to-high Dose Oral Corticosteroid Use in Patients with Dermatomyositis or Polymyositis
Abstract Number: 1052

Challenges and Opportunities in Post-Pandemic Remote Therapeutic Monitoring for Musculoskeletal Disease
Abstract Number: 1053

Pilot Intervention to Improve Medication Adherence Among Patients with Rheumatic Diseases
Abstract Number: 1054

Utilization of Rehabilitation Services in Patients with Common Rheumatic Conditions: A Systematic Review
Abstract Number: 1055

Impact of Provider Billing vs. Pharmacy Dispensation for Romosozumab Treatment Discontinuation Among U.S. Postmenopausal Women with Osteoporosis
Abstract Number: 1056

Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis
Abstract Number: 1057

Barriers and Facilitators of Access to Physical Therapy: A Scoping Review
Abstract Number: 1058

Bridging the Care Gap Between Hospital Discharge and Outpatient Care Transition for Pediatric Rheumatology Patients: An RN-led Quality Improvement Project
Abstract Number: 1059

The Negative Impact of Physicians’ Neuroticism and Conscientiousness on Shared Decision Making in Patients with Systemic Lupus Erythematosus: The TRUMP2-SLE Project

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].